 |
|
Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial
February 22, 2006Vical Incorporated (Nasdaq:VICL) announced today that an Ebola vaccine candidate administered using Vical's proprietary DNA delivery technology was safe and well tolerated, and produced both antibody and T-cell Ebola-specific responses in all healthy volunteers who received the full 3 doses of vaccine.
The Phase 1, randomized, placebo-controlled, dose-escalation study, the first human trial for any Ebola vaccine, was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and conducted at the NIH Clinical Center. The data were presented at the American Society for Microbiology (ASM) 2006 Biodefense Research Meeting in Washington, D.C., by Julie E. Martin, D.O., a trial investigator and research scientist at NIAID's Dale and Betty Bumpers Vaccine Research Center (VRC), which developed the vaccine. The DNA vaccine used in the Phase 1 trial incorporates genetic material encoding core and surface proteins from two strains of Ebola. Vical has secured a nonexclusive license from the NIH to proprietary gene sequences used in the vaccine.
The vaccine used in the Phase 1 trial vaccine included three plasmids (closed loops of DNA), one each encoding the surface glycoprotein (GP) from the Zaire strain of Ebola, GP from the Sudan/Gulu strain, and the internal nucleoprotein (NP) from the Zaire strain. Subjects received three doses of vaccine or placebo at one-month intervals via intramuscular needleless injection. Three cohorts tested progressively higher doses of the vaccine at 2 mg (5 subjects), 4 mg (8 subjects), or 8 mg (8 subjects - with 6 receiving the full three doses). Each cohort included two additional subjects who received placebo instead of active vaccine.
The vaccine was well tolerated, with no severe adverse reactions to the vaccine reported at any of the doses tested. Ebola-specific antibody responses against at least one of the encoded antigens were detected in all vaccine recipients. GP-specific antibody and T-cell responses were detected in all recipients who received the full three doses at all dose levels.
Porter Novelli, Life Sciences
Ebola Current Events and Ebola News RSS1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice
An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.
Outfoxing pox: Developing a new class of vaccine candidates
In the annals of medicine, Edward Jenner's 1796 vaccination of a young boy against smallpox, using fluid from cowpox blisters, remains a landmark case. In a new study, Kathryn Sykes, a researcher at Arizona State University's Biodesign Institute and her colleagues have taken a fresh look at cowpox.
World will miss 2010 target to stem biodiversity loss, experts say
The world will miss its agreed target to stem biodiversity loss by next year, according to experts convening in Cape Town for a landmark conference devoted to biodiversity science.
Scientists block Ebola infection in cell-culture experiments
Researchers at the University of Texas Medical Branch at Galveston have discovered two biochemical pathways that the Ebola virus relies on to infect cells.
OHSU scientists partner with others to form center aimed at combating infectious diseases
Oregon Health & Science University and the University of Washington, along with a number of partner institutions across the Northwest, have received federal funding to form a regional research center aimed at combating emerging or re-emerging infectious diseases that pose a serious threat to human health.
Drug blocks 2 of world's deadliest emerging viruses
Two highly lethal viruses that have emerged in recent outbreaks are susceptible to chloroquine, an established drug used to prevent and treat malaria, according to a new basic science study by researchers at Weill Cornell Medical College in the Journal of Virology.
Penn Study Identifies How Ebola Virus Avoids the Immune System
Researchers at the University of Pennsylvania School of Medicine have likely found one reason why the Ebola virus is such a powerful, deadly, and effective virus. Using a cell culture model for Ebola virus infection, they have discovered that the virus disables a cellular protein called tetherin that normally can block the spread of virus from cell to cell.
Iowa State University researchers discover structure of key Ebola protein
Research led by Iowa State University scientists has them a step closer to finding a way to counter the Ebola virus.
UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.
More Ebola Current Events and Ebola News Articles
 |
Ebola: Through the Eyes of the People by William T. Close (Author) At a Catholic Mission in Yambuku, an oasis of peace and efficiency in northern Congo's vast jungle forests, Mabalo Lokela, a teacher, receives an anti-malarial shot for a raging fever and headache. Sister Lucie, a Flemish nursing sister, swishes out a syringe with a weak disinfectant. The next patients are injected with the same syringe and the sick man's virus spreads. Lokela was the first Congolese victim of a new African hemorrhagic disease that became known as Ebola fever. When Sister Lucie dies a few days later, panic erupts and hospitalized patients flee into the forest. With the convent connected to the outside world by a single primitive radio, the mission nuns can only pray and wonder if anyone will act on their cries for help. |
 |
NOVA: Ebola - The Plague Fighters Starring: Nova Directed By: Nova Enter the "hot zone" of one of the most frightful diseases on the planet- Ebola. When a dreaded outbreak of the deadly Ebola virus swept through a remote region of Zaire in May 1995, NOVA was the only film crew permitted into the "hot zone." Spending a total of four weeks in the quarantined city of Kikwit, the result is unprecedented journalistic coverage of this grim battle against one of the world's most lethal diseases. The Ebola plague kills a very high percentage of its victims (77% in Kikwit), often by dissolving their internal organs and connective tissue. Learn how disease specialists traced the origins of the outbreak by compiling a complete "chain of death" of the epidemic, and why they fear a mutation of Ebola will emerge that is even more difficult to contain. |
 |
EBOLA GIANT MICROBE PLUSH by Giant Microbes Since its discovery in 1976, Ebola has become the T. Rex of microbes. Share the love! |
 |
Ebola by Dr. William Close (Author) IT STRIKES WITHOUT WARNING--A HORRIFYING, LETHAL DISEASE WITH NO NAME. AND NO CURE. . . . Now, from the molten center of the "hot zone," comes a terrifying, completely authentic novel of medical suspense by William T. Close, M.D., the American physician who lived in Zaire for sixteen years, and who worked desperately to contain the first outbreak of the virus in 1976. Haunted by the images from this wrenching time, and unable to forget the people he knew and lost, Dr. Close was compelled to tell their story. EBOLA, inspired by his personal experience and based upon extensive research, is an unforgettable portrait of this devastating drama, which all began with an invisible, unknown killer . . . . EBOLA At a Catholic mission in Yambuku, a remote area of Zaire, Mabalo Lokela, a local... |
 |
Emerging Viruses: AIDS And Ebola : Nature, Accident or Intentional? by Leonard G. Horowitz (Author) |
 |
Ebola Syndrome Starring: Anthony Wong Chau-Sang, Yeung Ming Wan, Fui-On Shing, Wong Tsui-ling, Miu-Ying Chan Directed By: Herman Yau Also With: Jing Wong (Producer), Ting Chau (Writer)
Kai San is a sleazy and despicable bastard of the most epic proportions! After being caught screwing the wife of his boss, he goes on a killing spree and flees Hong Kong. 10 years later, Kai finds himself working as a restaurant chef in South Africa. Overworked, underpaid, berated, and extorted by the restaurant owners who know of his fugitive status, Kai is a ticking timebomb... While visiting an ebola infected... |
 |
The Hot Zone: A Terrifying True Story by Richard Preston (Author) A highly infectious, deadly virus from the central African rain forest suddenly appears in the suburbs of Washington, D.C. There is no cure. In a few days 90 percent of its victims are dead. A secret military SWAT team of soldiers and scientists is mobilized to stop the outbreak of this exotic "hot" virus. The Hot Zone tells this dramatic story, giving a hair-raising account of the appearance of rare and lethal viruses and their "crashes" into the human race. Shocking, frightening, and impossible to ignore, The Hot Zone proves that truth really is scarier than fiction. From the Paperback edition. |
 |
Ebola Mini Plush in Petri Dish by Giant Microbes by Giant Microbes set of 3 MiniPlush Ebola viruses in therir very own petri dish by Giant Microbes |
 |
NOVA: Epidemic - Ebola, AIDS, Bird Flu and Typhoid Starring: Nova Directed By: Nova Includes four programs: NOVA-Ebola The Plague Fighters; NOVA-Surviving AIDS, NOVA-Typhoid Mary: The Most Dangerous Woman in America; and Rx for Survival-Bird Flu. |
 |
Ebola (Deadly Diseases and Epidemics) by Tara C. Smith (Author) |
| © 2009 BrightSurf.com |